Cargando…

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder

Objectives: To evaluate the short-term efficacy and safety of desvenlafaxine (25–50 mg/d) compared with placebo in children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years) who met DSM-IV-TR criteria for MDD and had screeni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weihs, Karen L., Murphy, William, Abbas, Richat, Chiles, Deborah, England, Richard D., Ramaker, Sara, Wajsbrot, Dalia B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771543/ https://www.ncbi.nlm.nih.gov/pubmed/29189044 http://dx.doi.org/10.1089/cap.2017.0100

Ejemplares similares

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
por: Atkinson, Sarah, et al.
Publicado: (2018)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression
por: Zilcha-Mano, Sigal, et al.
Publicado: (2021)

Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
por: Ch, Saritha, et al.
Publicado: (2022)

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
por: Lieberman, Daniel Z, et al.
Publicado: (2010)

Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine
por: Benoit, James R.A., et al.
Publicado: (2021)

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder
por: Liebowitz, Michael R, et al.
Publicado: (2013)

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
por: Soares, Claudio N., et al.
Publicado: (2019)

Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial
por: Gupta, Brij Mohan, et al.
Publicado: (2016)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
por: Bhatia, Anu, et al.
Publicado: (2018)

Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression
por: ZAMANIAN, Abbas, et al.
Publicado: (2017)

Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study
por: Wigal, Sharon B., et al.
Publicado: (2018)

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
por: Lyndon, Gavin J., et al.
Publicado: (2019)

Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study
por: Amr, Mostafa, et al.
Publicado: (2013)

The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis
por: Khaksarian, Mojtaba, et al.
Publicado: (2019)

Serum levels of chemokines in adolescents with major depression treated with fluoxetine
por: de la Peña, Francisco Rafael, et al.
Publicado: (2020)

Venlafaxine and desvenlafaxine in the management of menopausal hot flashes
por: Johnson, Emily D, et al.
Publicado: (2011)

PS210. Effect of Desvenlafaxine on Altered Heart Rate Variability in Persistent Depressive Disorder
por: Ravindran, Arun V., et al.
Publicado: (2016)

Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study
por: Ventura-Juncá, Raúl, et al.
Publicado: (2014)

Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial
por: Mahajan, Sonia Shinde, et al.
Publicado: (2019)

6-Sulfatoxymelatonin predicts treatment response to fluoxetine in major depressive disorder
por: Jury Freitas, Juliana, et al.
Publicado: (2019)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low, Yvette, et al.
Publicado: (2018)

Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report
por: Flora, Arjan, et al.
Publicado: (2018)

PS100. Open-label Desvenlafaxine as Monotherapy for Persistent Depression Disorder: A Pilot Study
por: Ravindran, Arun V., et al.
Publicado: (2016)

Multidisciplinar treatment in postpartum depression. Coordinated attention of psychiatrist and midwife: use of desvenlafaxine while breastfeeding
por: Sánchez Rus, S.S., et al.
Publicado: (2022)

Nortriptyline versus fluoxetine in the treatment of major depressive disorder: a six-month, double-blind clinical trial
por: Hashemi, SN, et al.
Publicado: (2012)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder
por: Brunner, Elizabeth, et al.
Publicado: (2014)

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
por: Bousman, Chad A., et al.
Publicado: (2017)

Prenatal desvenlafaxine induced behavioural alterations in Swiss albino mice
por: Kumari, Amrita, et al.
Publicado: (2014)

Desvenlafaxine-associated hyperglycemia: A case report and literature review
por: Mekonnen, Andrea D., et al.
Publicado: (2020)

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets
por: Carapeto, Gustavo Vaiano, et al.
Publicado: (2023)

Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study
por: Chen, Yiyi, et al.
Publicado: (2019)

Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression
por: Shahsavand Ananloo, Esmaeil, et al.
Publicado: (2013)

Changes in the levels of comet parameters before and after fluoxetine therapy in major depression patients
por: Panwar, Rajeev, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_49b2kcb8osvaf9snjum8fnu814